Drugs that increase INS secretion, such as sulfonylureas, glinides, and glucagon-like peptide-1 receptor agonists, are widely used in the management of T2DM [2]; however, these drugs often have undesirable side effects. The gene discussed is INS; the disease is type 2 diabetes mellitus.